Search Results

There are 11513 results for: content related to: The cannabinoid CB 1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA A receptors

  1. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies

    Addiction Biology

    Volume 13, Issue 2, June 2008, Pages: 239–252, Bernard Le Foll, Benoit Forget, Henri-Jean Aubin and Steven R. Goldberg

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1369-1600.2008.00113.x

  2. You have free access to this content
    Effects of Chronic Oral Rimonabant Administration on Energy Budgets of Diet-Induced Obese C57BL/6 Mice

    Obesity

    Volume 20, Issue 5, May 2012, Pages: 954–962, Li-Na Zhang, Yuko Gamo, Rachel Sinclair, Sharon E. Mitchell, David G. Morgan, John C. Clapham and John R. Speakman

    Version of Record online : 10 SEP 2012, DOI: 10.1038/oby.2011.357

  3. You have free access to this content
    The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure

    Obesity

    Volume 17, Issue 2, February 2009, Pages: 254–261, Aaron N.A. Verty, Andrew M. Allen and Brian J. Oldfield

    Version of Record online : 6 SEP 2012, DOI: 10.1038/oby.2008.509

  4. You have free access to this content
    Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral-Antagonist/Inverse-Agonist Therapies

    Obesity

    Volume 19, Issue 7, July 2011, Pages: 1325–1334, Sara Jane Ward and Robert B. Raffa

    Version of Record online : 10 SEP 2012, DOI: 10.1038/oby.2011.69

  5. Rimonabant for overweight or obesity

    Intervention Review

    The Cochrane Library

    Cintia Curioni and Charles André

    Published Online : 18 OCT 2006, DOI: 10.1002/14651858.CD006162.pub2

  6. You have free access to this content
    Effect of the Cannabinoid Receptor-1 Antagonist Rimonabant on Inflammation in Mice With Diet-Induced Obesity

    Obesity

    Volume 19, Issue 3, March 2011, Pages: 505–513, Qun Wang, Xiaoyuan D. Perrard, Jerry L. Perrard, Amir Mansoori, C. Wayne Smith, Christie M. Ballantyne and Huaizhu Wu

    Version of Record online : 6 SEP 2012, DOI: 10.1038/oby.2010.213

  7. Cannabinoid type 1 receptor antagonists for smoking cessation

    Intervention Review

    The Cochrane Library

    Kate Cahill and Michael H Ussher

    Published Online : 16 MAR 2011, DOI: 10.1002/14651858.CD005353.pub4

  8. You have free access to this content
    Effects on Food Intake and Blood Lipids of Cannabinoid Receptor 1 Antagonist Treatment in Lean Rats

    Obesity

    Volume 16, Issue 11, November 2008, Pages: 2451–2455, Marianne F. Bennetzen, Maria P. Nielsen, Bjørn Richelsen and Steen B. Pedersen

    Version of Record online : 6 SEP 2012, DOI: 10.1038/oby.2008.390

  9. Differential regulation of NMDAR and NMDAR-mediated metaplasticity by anandamide and 2-AG in the hippocampus

    Hippocampus

    Volume 24, Issue 12, December 2014, Pages: 1601–1614, Kai Yang, Gang Lei, Yu-Feng Xie, John F. MacDonald and Michael F. Jackson

    Version of Record online : 20 AUG 2014, DOI: 10.1002/hipo.22339

  10. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 7, July 2010, Pages: 591–603, L. Zhang, N. J. Lee, A. D. Nguyen, R. F. Enriquez, S. J. Riepler, B. Stehrer, E. Yulyaningsih, S. Lin, Y. C. Shi, P. A. Baldock, H. Herzog and A. Sainsbury

    Version of Record online : 21 DEC 2009, DOI: 10.1111/j.1463-1326.2009.01193.x

  11. You have free access to this content
    CB1-independent mechanisms of Δ9-THCV, AM251 and SR141716 (rimonabant)

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 3, June 2012, Pages: 260–265, R. B. Raffa and S. J. Ward

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2710.2011.01284.x

  12. You have free access to this content
    The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction

    Addiction Biology

    Volume 13, Issue 2, June 2008, Pages: 160–187, José Antonio López-Moreno, Gustavo González-Cuevas, Guillermo Moreno and Miguel Navarro

    Version of Record online : 16 APR 2008, DOI: 10.1111/j.1369-1600.2008.00105.x

  13. You have free access to this content
    The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use

    Journal of Clinical Pharmacy and Therapeutics

    Volume 32, Issue 3, June 2007, Pages: 209–231, S. Xie, M. A. Furjanic, J. J. Ferrara, N. R. McAndrew, E. L. Ardino, A. Ngondara, Y. Bernstein, K. J. Thomas, E. Kim, J. M. Walker, S. Nagar, S. J. Ward and R. B. Raffa

    Version of Record online : 2 MAY 2007, DOI: 10.1111/j.1365-2710.2007.00817.x

  14. Effect of antiobesity medications in patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 7, July 2009, Pages: 641–664, Souzana Choussein, Angeliki A. Makri, Constantinos C. Frangos, Eleni Th. Petridou and Stella S. Daskalopoulou

    Version of Record online : 18 FEB 2009, DOI: 10.1111/j.1463-1326.2008.01026.x

  15. You have free access to this content
    Efficacy of Rimonabant and Other Cannabinoid CB1 Receptor Antagonists in Reducing Food Intake and Body Weight: Preclinical and Clinical Data

    CNS Drug Reviews

    Volume 12, Issue 2, June 2006, Pages: 91–99, Mauro A. M. Carai, Giancarlo Colombo, Paola Maccioni and Gian Luigi Gessa

    Version of Record online : 29 AUG 2006, DOI: 10.1111/j.1527-3458.2006.00091.x

  16. You have free access to this content
    Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon

    International Journal of Cancer

    Volume 125, Issue 5, 1 September 2009, Pages: 996–1003, Antonietta Santoro, Simona Pisanti, Claudia Grimaldi, Angelo A. Izzo, Francesca Borrelli, Maria C. Proto, Anna M. Malfitano, Patrizia Gazzerro, Chiara Laezza and Maurizio Bifulco

    Version of Record online : 6 APR 2009, DOI: 10.1002/ijc.24483

  17. Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic Promises

    Chemistry & Biodiversity

    Volume 4, Issue 8, August 2007, Pages: 1805–1827, Giulio G. Muccioli

    Version of Record online : 21 AUG 2007, DOI: 10.1002/cbdv.200790153

  18. The cannabinoid receptor 1 and its role in influencing peripheral metabolism

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 4, April 2014, Pages: 294–304, L. O'Keefe, A. C. Simcocks, D. H. Hryciw, M. L. Mathai and A. J. McAinch

    Version of Record online : 10 JUL 2013, DOI: 10.1111/dom.12144

  19. You have free access to this content
    The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys

    British Journal of Pharmacology

    Volume 164, Issue 2b, September 2011, Pages: 655–666, Jennifer L Stewart and Lance R McMahon

    Version of Record online : 28 AUG 2011, DOI: 10.1111/j.1476-5381.2011.01388.x

  20. The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome

    The Journal of Clinical Pharmacology

    Volume 47, Issue 5, May 2007, Pages: 642–652, Dr Anna I. Kakafika, Dr Dimitri P. Mikhailidis, Dr Asterios Karagiannis and Dr Vasilios G. Athyros

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007299358